

Drug Monograph

Drug/Drug **Arymo ER[®] (morphine sulfate) extended release tablet/**
 Class: **Long Acting Opioids**
 Prepared for: MO HealthNet
 Prepared by: Conduent-Heritage

New Criteria

Revision of Existing Criteria

Executive Summary

Purpose: The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

Dosage Forms: Arymo ER[®] is available in an extended release tablet containing 15 mg, 30 mg, and 60 mg of morphine sulfate respectively.

Manufacturer: Egalet US Inc., Wayne, PA 19087

Indications: Arymo ER[®] is indicated for the management of pain severe enough to require daily, around the clock, long term opioid treatment and for which alternative treatment options are inadequate.

Costs: \$4.32 per 15 mg tablet, \$8.65 per 30 mg tablet, and \$17.30 per 60 mg tablet of Arymo ER[®]. Wholesale Acquisition Cost

Summary of Findings: This drug is being considered for inclusion in the state specific Preferred Drug List (PDL).

Status Recommendation:

<input type="checkbox"/> Prior Authorization (PA) Required	<input type="checkbox"/> Open Access
<input type="checkbox"/> Fiscal Edit	<input checked="" type="checkbox"/> PDL

Type of PA Criteria:

<input type="checkbox"/> Increased Risk of ADE	<input checked="" type="checkbox"/> Under Solicitation
<input type="checkbox"/> Appropriate Indications	<input type="checkbox"/> Non Preferred

Prepared By: Luke Boehmer Pharm.D.
 Date: August 4, 2017